Sarcopenia, obesity, and natural killer cell immune senescence in aging: Altered cytokine levels as a common mechanism

Aging

Volumn 4, Issue 8, 2012, Pages 535-546

  Lutz, Charles T ^a   Quinn, LeBris S ^b,c,d  

^a UNIVERSITY OF KENTUCKY   (United States)

^b VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d Seattle Institute for Biomedical and Clinical Research   (United States)

Author keywords

Adipose tissue; Aging; Immunity; Natural killer lymphocytes; Obesity; Sarcopenia; Skeletal muscle

Indexed keywords

EID: 84868029429     PISSN: 19454589     EISSN: None     Source Type: Journal    
DOI: 10.18632/aging.100482     Document Type: Review

References (141)

1. Roubenoff R. Sarcopenic obesity: does muscle loss cause fat gain?: lessons from rheumatoid arthritis and osteoarthritis. Ann NY Acad Sci. 2000; 904:553-557.
2. Gaziano JM. Fifth phase of the epidemiologic transition: the age of obesity and inactivity. JAMA. 2010; 303:275-276.
3. Pedersen BK. The diseasome of physical inactivity - and the role of myokines in muscle-fat cross talk. J Physiol. 2009; 587:5559-5568.
4. Faulkner JA, Larkin LM, Claflin DR and Brooks SV. Age-related changes in the structure and function of skeletal muscles. Clin Exp Pharmacol Physiol. 2007; 34:1091-1096.
5. Narici MV and Maffulli N. Sarcopenia: characteristics, mechanisms and functional significance. Br Med Bull. 2010:ldq008.
6. Korhonen MT, Cristea A, Alen M, Hakkinen K, Sipila S, Mero A, Viitasalo JT, Larsson L and Suominen H. Aging, muscle fiber type, and contractile function in sprint-trained athletes. J Appl Physiol. 2006; 101:906-917.
7. Welle S, Totterman S and Thornton C. Effect of age on muscle hypertrophy induced by resistance training. J Gerontol A Biol Sci Med Sci. 1996; 51:M270-275.
8. Burks TN and Cohn RD. One size may not fit all: anti-aging therapies and sarcopenia. Aging (Albany NY). 2011; 3:1142-1153.
9. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, Seeman T, Tracy R, Kop WJ, Burke G, McBurnie MA and Cardiovascular HSCRG. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001; 56A:M146-156.
10. Searle S, Mitnitski A, Gahbauer E, Gill T and Rockwood K. A standard procedure for creating a frailty index. BMC Geriatrics. 2008; 8:24.
11. Flegal KM, Carroll MD, Ogden CL and Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA. 2010; 303:235-241.
12. Ogden CL, Carroll MD, Curtin LR, Lamb MM and Flegal KM. Prevalence of high body mass index in US children and adolescents, 2007-2008. JAMA. 2010; 303:242-249.
13. Pischon T, Boeing H, Hoffmann K, Bergmann M, Schulze MB, Overvad K, van der Schouw YT, Spencer E, Moons KGM, Tjønneland A, Halkjaer J, Jensen MK, Stegger J, et al. General and abdominal adiposity and risk of death in europe. New Engl J Med. 2008; 359:2105-2120.
14. Delmonico MJ, Harris TB, Visser M, Park SW, Conroy MB, Velasquez-Mieyer P, Boudreau R, Manini TM, Nevitt M, Newman AB and Goodpaster BH. Longitudinal study of muscle strength, quality, and adipose tissue infiltration. Am J Clin Nutr. 2009; 90:1579-1585.
15. Sitnick M, Bodine SC and Rutledge JC. Chronic high fat feeding attenuates load-induced hypertrophy in mice. J Physiol. 2009; 587:5753-5765.
16. Williamson DL and Drake JC. Normalizing a hyperactive mTOR initiates muscle growth during obesity. Aging (Albany NY). 2011; 3:83-84.
17. Larbi A, Franceschi C, Mazzatti D, Solana R, Wikby A and Pawelec G. Aging of the immune system as a prognostic factor for human longevity. Physiology (Bethesda). 2008; 23:64-74.
18. Wikby A, Johansson B, Olsson J, Löfgren S, Nilsson B-O and Ferguson F. Expansions of peripheral blood CD8 T-lymphocyte subpopulations and an association with cytomegalovirus seropositivity in the elderly: the Swedish NONA immune study. Exp Gerontol. 2002; 37:445-453.
19. Shaw AC, Joshi S, Greenwood H, Panda A and Lord JM. Aging of the innate immune system. Curr Opin Immunology. 2010; 22:507-513.
20. Wikby A, Ferguson F, Forsey R, Thompson J, Strindhall J, Löfgren S, Nilsson B-O, Ernerudh J, Pawelec G and Johansson B. An immune risk phenotype, cognitive impairment, and survival in very late life: impact of allostatic load in Swedish octogenarian and nonagenarian humans. J Gerontol A Biol Sci Med Sci. 2005; 60:556-565.
21. Lutz CT, Karapetyan A, Al-Attar A, Shelton BJ, Holt KJ, Tucker JH and Presnell SR. Human NK cells proliferate and die in vivo more rapidly than T cells in healthy young and elderly adults. J Immunol. 2011; 186:4590-4598.
22. Facchini A, Mariani E, Mariani AR, Papa S, Vitale M and Manzoli FA. Increased number of circulating Leu 11+ (CD 16) large granular lymphocytes and decreased NK activity during human ageing. Clin Exp Immunol. 1987; 68:340-347.
23. Imai K, Matsuyama S, Miyake S, Suga K and Nakachi K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet. 2000; 356:1795-1799.
24. Solana R and Mariani E. NK and NK/T cells in human senescence. Vaccine. 2000; 18:1613-1620.
25. Pedersen BK. Muscles and their myokines. J Exp Biol. 2011; 214:337-346.
26. Stefanyk LE and Dyck DJ. The interaction between adipokines, diet and exercise on muscle insulin sensitivity. Curr Opin Clin Nutr Metab Care. 2010; 13:255-259.
27. Tilg H and Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol. 2006; 6:772-783.
28. Tilg H and Moschen AR. Role of adiponectin and PBEF/visfatin as regulators of inflammation: involvement in obesity-associated diseases. Clin Sci. 2008; 114:275-288.
29. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL and Ferrante AW. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003; 112:1796-1808.
30. Duffaut C, Galitzky J, Lafontan M and Bouloumié A. Unexpected trafficking of immune cells within the adipose tissue during the onset of obesity. Biochem Biophys Res Commun. 2009; 384:482-485.
31. Caspar-Bauguil S, Cousin B, Galinier A, Segafredo C, Nibbelink M, André M, Casteilla L and Pénicaud L. Adipose tissues as an ancestral immune organ: Site-specific change in obesity. FEBS Letters. 2005; 579:3487-3492.
32. O'Rourke RW, Metcalf MD, White AE, Madala A, Winters BR, Maizlin II, Jobe BA, Roberts CT, Jr., Slifka MK and Marks DL. Depot-specific differences in inflammatory mediators and a role for NK cells and IFN-g in inflammation in human adipose tissue. Int J Obes. 2009; 33:978-990.
33. Lumeng CN, Maillard I and Saltiel AR. T-ing up inflammation in fat. Nat Med. 2009; 15:846-847.
34. O'Rourke RW, White AE, Metcalf MD, Winters BR, Diggs BS, Zhu X and Marks DL. Systemic inflammation and insulin sensitivity in obese IFN-g knockout mice. Metabolism. 2012.
35. O'Rourke RW, White AE, Metcalf MD, Olivas AS, Mitra P, Larison WG, Cheang EC, Varlamov O, Corless CL, Roberts CT, Jr. and Marks DL. Hypoxia-induced inflammatory cytokine secretion in human adipose tissue stromovascular cells. Diabetologia. 2011; 54:1480-1490.
36. Vilarrasa N, Vendrell J, Maravall J, Broch M, Estepa A, Megia A, Soler J, Simon I, Richart C and Gomez JM. Distribution and determinants of adiponectin, resistin and ghrelin in a randomly selected healthy population. Clin Endocrinol (Oxf). 2005; 63:329-335.
37. Kim K-y, Kim JK, Han SH, Lim J-S, Kim KI, Cho DH, Lee M-S, Lee J-H, Yoon D-Y, Yoon SR, Chung JW, Choi I, Kim E, et al. Adiponectin is a negative regulator of NK cell cytotoxicity. J Immunol. 2006; 176:5958-5964.
38. Zarkesh-Esfahani H, Pockley G, Metcalfe RA, Bidlingmaier M, Wu Z, Ajami A, Weetman AP, Strasburger CJ and Ross RJM. Highdose leptin activates human leukocytes wia receptor expression on monocytes. J Immunol. 2001; 167:4593-4599.
39. Tian Z, Sun R, Wei H and Gao B. Impaired natural killer (NK) cell activity in leptin receptor deficient mice: leptin as a critical regulator in NK cell development and activation. Biochem Biophys Res Commun. 2002; 298:297-302.
40. Meyers JA, Liu AY, McTiernan A, Wener MH, Wood B, Weigle DS, Sorensen B, Chen-Levy Z, Yasui Y, Boynton A, Potter JD and Ulrich CM. Serum leptin concentrations and markers of immune function in overweight or obese postmenopausal women. J Endocrinol. 2008; 199:51-60.
41. Kelesidis T, Kelesidis I, Chou S and Mantzoros CS. Narrative review: the role of leptin in human physiology: emerging clinical applications. Ann Intern Med. 2010; 152:93-100.
42. Wrann CD, Laue T, Hubner L, Kuhlmann S, Jacobs R, Goudeva L and Nave H. Short-term and long-term leptin exposure differentially affect human natural killer cell immune functions. Am J Physiol Endocrinol Metab. 2012; 302:E108-116.
43. Nave H, Mueller G, Siegmund B, Jacobs R, Stroh T, Schueler U, Hopfe M, Behrendt P, Buchenauer T, Pabst R and Brabant G. Resistance of Janus kinase-2 dependent leptin signaling in natural killer (NK) cells: a novel mechanism of NK cell dysfunction in diet-induced obesity. Endocrinology. 2008; 149:3370-3378.
44. Wang ZW, Pan WT, Lee Y, Kakuma T, Zhou YT and Unger RH. The role of leptin resistance in the lipid abnormalities of aging. FASEB J. 2001; 15:108-114.
45. Bondue B, Wittamer V and Parmentier M. Chemerin and its receptors in leukocyte trafficking, inflammation and metabolism. Cytokine Growth Factor Rev. 2011; 22:331-338.
46. Alfadda AA, Sallam RM, Chishti MA, Moustafa AS, Fatma S, Alomaim WS, Al-Naami MY, Bassas AF, Chrousos GP and Jo H. Differential patterns of serum concentration and adipose tissue expression of chemerin in obesity: Adipose depot specificity and gender dimorphism. Mol Cells. 2012.
47. Bokarewa M, Nagaev I, Dahlberg L, Smith U and Tarkowski A. Resistin, an adipokine with potent proinflammatory properties. J Immunol. 2005; 174:5789-5795.
48. McTernan CL, McTernan PG, Harte AL, Levick PL, Barnett AH and Kumar S. Resistin, central obesity, and type 2 diabetes. The Lancet. 2002; 359:46-47.
49. Azuma K, Katsukawa F, Oguchi S, Murata M, Yamazaki H, Shimada A and Saruta T. Correlation between serum resistin level and adiposity in obese individuals. Obesity. 2003; 11:997-1001.
50. Jia SH, Li Y, Parodo J, Kapus A, Fan L, Rotstein OD and Marshall JC. Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J Clin Invest. 2004; 114:141-141.
51. Krzysik-Walker SM, Ocon-Grove OM, Maddineni SR, Hendricks GL, III and Ramachandran R. Is visfatin an adipokine or myokine? Evidence for greater visfatin expression in skeletal muscle than visceral fat in chickens. Endocrinology. 2008; 149:1543-1550.
52. Varma V, Yao-Borengasser A, Rasouli N, Bodles AM, Phanavanh B, Lee M-J, Starks T, Kern LM, Spencer HJ, III, McGehee RE, Jr., Fried SK and Kern PA. Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation. J Clin Endocrinol Metab. 2007; 92:666-672.
53. Costford SR, Bajpeyi S, Pasarica M, Albarado DC, Thomas SC, Xie H, Church TS, Jubrias SA, Conley KE and Smith SR. Skeletal muscle NAMPT is induced by exercise in humans. Am J Physiol Endocrinol Metab. 2010; 298:E117-E126.
54. Garten A, Petzold S, Körner A, Imai S-i and Kiess W. Nampt: linking NAD biology, metabolism and cancer. Trends Endocrinol Metab. 2009; 20:130-138.
55. Tracey KJ and Cerami A. Tumor necrosis factor, other cytokines and disease. Ann Rev Cell Biol. 1993; 9:317-343.
56. Saghizadeh M, Ong JM, Garvey WT, Henry RR and Kern PA. The expression of TNFa by human muscle. Relationship to insulin resistance. J Clin Invest. 1996; 97:1111-1116.
57. De Rossi M, Bernasconi P, Baggi F, de Waal Malefyt R and Mantegazza R. Cytokines and chemokines are both expressed by human myoblasts: possible relevance for the immune pathogenesis of muscle inflammation. International Immunol. 2000; 12:1329-1335.
58. Lumeng CN, Bodzin JL and Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest. 2007; 117:175-184.
59. Hotamisligil GS, Shargill NS and Spiegelman BM. Adipose expression of tumor necrosis factor-a: direct role in obesitylinked insulin resistance. Science. 1993; 259:87-91.
60. Singh T and Newman AB. Inflammatory markers in population studies of aging. Ageing Res Rev. 2011; 10:319-329.
61. Alvarez-Rodriguez L, Lopez-Hoyos M, Munoz-Cacho P and Martinez-Taboada VM. Aging is associated with circulating cytokine dysregulation. Cell Immunol. 2012; 273:124-132.
62. Jewett A, Cavalcanti M and Bonavida B. Pivotal role of endogenous TNF-a in the induction of functional inactivation and apoptosis in NK cells. J Immunol. 1997; 159:4815-4822.
63. Ross ME and Caligiuri MA. Cytokine-induced apoptosis of human natural killer cells identifies a novel mechanism to regulate the innate immune response. Blood. 1997; 89:910-918.
64. Gupta S and Gollapudi S. TNF-a-induced apoptosis in human naïve and memory CD8+ T cells in aged humans. Exp Gerontol. 2006; 41:69-77.
65. Cesari M, Kritchevsky SB, Baumgartner RN, Atkinson HH, Penninx BWHJ, Lenchik L, Palla SL, Ambrosius WT, Tracy RP and Pahor M. Sarcopenia, obesity, and inflammation--results from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors study. Am J Clin Nutr. 2005; 82:428-434.
66. Schrager MA, Metter EJ, Simonsick E, Ble A, Bandinelli S, Lauretani F and Ferrucci L. Sarcopenic obesity and inflammation in the InCHIANTI study. J Appl Physiol. 2007; 102:919-925.
67. Forsey RJ, Thompson JM, Ernerudh J, Hurst TL, Strindhall J, Johansson B, Nilsson BO and Wikby A. Plasma cytokine profiles in elderly humans. Mech Ageing Dev. 2003; 124:487-493.
68. Carson JA and Baltgalvis KA. Interleukin 6 as a key regulator of muscle mass during cachexia. Exerc Sport Sci Rev. 2010; 38:168-176.
69. Korn T, Mitsdoerffer M, Croxford AL, Awasthi A, Dardalhon VA, Galileos G, Vollmar P, Stritesky GL, Kaplan MH, Waisman A, Kuchroo VK and Oukka M. IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cells. Proc Natl Acad Sci U S A. 2008; 105:18460-18465.
70. Passos ST, Silver JS, O'Hara AC, Sehy D, Stumhofer JS and Hunter CA. IL-6 promotes NK cell production of IL-17 during Toxoplasmosis. J Immunol. 2010; 184:1776-1783.
71. Starkie R, Ostrowski SR, Jauffred S, Febbraio M and Pedersen BK. Exercise and IL-6 infusion inhibit endotoxin-induced TNF-a production in humans. FASEB J. 2003; 17:884-886.
72. Steensberg A, Fischer CP, Keller C, Moller K and Pedersen BK. IL-6 enhances plasma IL-1ra, IL-10, and cortisol in humans. Am J Physiol Endocrinol Metab. 2003; 285:E433-437.
73. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol. 2009; 27:519-550.
74. Stienstra R, Tack CJ, Kanneganti TD, Joosten LA and Netea MG. The inflammasome puts obesity in the danger zone. Cell Metab. 2012; 15:10-18.
75. Hughes T, Becknell B, Freud AG, McClory S, Briercheck E, Yu J, Mao C, Giovenzana C, Nuovo G, Wei L, Zhang X, Gavrilin MA, Wewers MD, et al. Interleukin-1b selectively expands and sustains interleukin-22+ immature human natural killer cells in secondary lymphoid tissue. Immunity. 2010; 32:803-814.
76. Cella M, Otero K and Colonna M. Expansion of human NK-22 cells with IL-7, IL-2, and IL-1beta reveals intrinsic functional plasticity. Proc Natl Acad Sci U S A. 2010; 107:10961-10966.
77. Cooper MA, Fehniger TA, Ponnappan A, Mehta V, Wewers MD and Caligiuri MA. Interleukin-1b costimulates interferon-g production by human natural killer cells. Eur J Immunol. 2001; 31:792-801.
78. Esposito K, Pontillo A, Giugliano F, Giugliano G, Marfella R, Nicoletti G and Giugliano D. Association of low interleukin-10 levels with the metabolic syndrome in obese women. J Clin Endocrinol Metab. 2003; 88:1055-1058.
79. Chelvarajan RL, Collins SM, Van Willigen JM and Bondada S. The unresponsiveness of aged mice to polysaccharide antigens is a result of a defect in macrophage function. J Leukoc Biol. 2005; 77:503-512.
80. Chiu BC, Stolberg VR and Chensue SW. Mononuclear phagocyte-derived IL-10 suppresses the innate IL-12/IFN-gamma axis in lung-challenged aged mice. J Immunol. 2008; 181:3156-3166.
81. Pestka S, Krause CD, Sarkar D, Walter MR, Shi Y and Fisher PB. Interleukin-10 and related cytokines and receptors. Annu Rev Immunol. 2004; 22:929-979.
82. Carson WE, Lindemann MJ, Baiocchi R, Linett M, Tan JC, Chou CC, Narula S and Caligiuri MA. The functional characterization of interleukin-10 receptor expression on human natural killer cells. Blood. 1995; 85:3577-3585.
83. Stacey MA, Marsden M, Wang EC, Wilkinson GW and Humphreys IR. IL-10 restricts activation-induced death of NK cells during acute murine cytomegalovirus infection. J Immunol. 2011; 187:2944-2952.
84. Li MO, Wan YY, Sanjabi S, Robertson AK and Flavell RA. Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol. 2006; 24:99-146.
85. Spencer M, Yao-Borengasser A, Unal R, Rasouli N, Gurley CM, Zhu B, Peterson CA and Kern PA. Adipose tissue macrophages in insulin-resistant subjects are associated with collagen VI and fibrosis and demonstrate alternative activation. Am J Physiol Endocrinol Metab. 2010; 299:E1016-1027.
86. Nieman DC, Henson DA, Nehlsen-Cannarella SL, Ekkens M, Utter AC, Butterworth DE and Fagoaga OR. Influence of obesity on immune function. J Am Diet Assoc. 1999; 99:294-299.
87. Dovio A, Caramello V, Masera RG, Sartori ML, Saba L, Tinivella M, Prolo P, Termine A, Avagnina P and Angeli A. Natural killer cell activity and sensitivity to positive and negative modulation in uncomplicated obese subjects: relationships to leptin and diet composition. Int J Obes. 2004; 28:894-901.
88. Lynch LA, O'Connell JM, Kwasnik AK, Cawood TJ, O'Farrelly C and O'Shea DB. Are natural killer cells protecting the metabolically healthy obese patient? Obesity. 2008; 17:601-605.
89. Moulin CM, Marguti I, Peron JP, Halpern A and Rizzo LV. Bariatric surgery reverses natural killer (NK) cell activity and NKrelated cytokine synthesis impairment induced by morbid obesity. Obes Surg. 2011; 21:112-118.
90. Lim KI, Yang SJ, Kim TN, Yoo HJ, Kang HJ, Song W, Baik SH, Choi DS and Choi KM. The association between the ratio of visceral fat to thigh muscle area and metabolic syndrome: the Korean Sarcopenic Obesity Study (KSOS). Clin Endocrinol (Oxf). 2010; 73:588-594.
91. Sayer AA, Syddall HE, Dennison EM, Martin HJ, Phillips DI, Cooper C and Byrne CD. Grip strength and the metabolic syndrome: findings from the Hertfordshire Cohort Study. QJM. 2007; 100:707-713.
92. Alpdogan O, Muriglan SJ, Kappel BJ, Doubrovina E, Schmaltz C, Schiro R, Eng JM, Greenberg AS, Willis LM, Rotolo JA, O'Reilly RJ and van den Brink MR. Insulin-like growth factor-I enhances lymphoid and myeloid reconstitution after allogeneic bone marrow transplantation. Transplantation. 2003; 75:1977-1983.
93. Kooijman R, Willems M, De Haas CJ, Rijkers GT, Schuurmans AL, Van Buul-Offers SC, Heijnen CJ and Zegers BJ. Expression of type I insulin-like growth factor receptors on human peripheral blood mononuclear cells. Endocrinology. 1992; 131:2244-2250.
94. Grabstein KH, Eisenman J, Shanebeck K, Rauch C, Srinivasan S, Fung V, Beers C, Richardson J, Schoenborn MA, Ahdieh M, Watson JD, Anderson DM and Giri JA. Cloning of a T cell growth factor that interacts with the b chain of the interleukin-2 receptor. Science. 1994; 264:965-968.
95. Waldmann TA and Tagaya Y. The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. Annu Rev Immunol. 1999; 17:19-49.
96. Bergamaschi C, Rosati M, Jalah R, Valentin A, Kulkarni V, Alicea C, Zhang G-M, Patel V, Felber BK and Pavlakis GN. Intracellular interaction of interleukin-15 with its receptor a during production leads to mutual stabilization and increased bioactivity. J Biol Chem. 2008; 283:4189-4199.
97. Mortier E, Woo T, Advincula R, Gozalo S and Ma A. IL-15Ra chaperones IL-15 to stable dendritic cell membrane complexes that activate NK cells via trans presentation. J Exp Med. 2008; 205:1213-1225.
98. Mortier E, Bernard J, Plet A and Jacques Y. Natural, proteolytic release of a soluble form of human IL-15 receptor achain that behaves as a specific, high affinity IL-15 antagonist. J Immunol. 2004; 173:1681-1688.
99. Badoual C, Bouchaud G, Agueznay NEH, Mortier E, Hans S, Gey A, Fernani F, Peyrard S, Puig PL, Bruneval P, Sastre X, Plet A, Garrigue-Antar L, et al. The soluble a chain of interleukin-15 receptor: a proinflammatory molecule associated with tumor progression in head and neck cancer. Cancer Res. 2008; 68:3907-3914.
100. Bouchaud G, Garrigue-Antar L, Solé V, Quéméner A, Boublik Y, Mortier E, Perdreau H, Jacques Y and Plet A. The exon-3- encoded domain of IL-15Ra contributes to IL-15 high-affinity binding and is crucial for the IL-15 antagonistic effect of soluble IL-15Ra. J Mol Biol. 2008; 382:1-12.
101. Bouchaud G, Mortier E, Flamant M, Barbieux I, Plet A, Galmiche J-P, Jacques Y and Bourreille A. Interleukin-15 and its soluble receptor mediate the response to infliximab in patients with crohn's disease. Gastroenterol. 2010; 138:2378-2387.
102. Barra NG, Reid S, MacKenzie R, Werstuck G, Trigatti BL, Richards C, Holloway AC and Ashkar AA. Interleukin-15 contributes to the regulation of murine adipose tissue and human adipocytes. Obesity. 2010.
103. Stoklasek TA, Schluns KS and Lefrancois L. Combined IL- 15/IL-15Ra immunotherapy maximizes IL-15 activity in vivo. J Immunol. 2006; 177:6072-6080.
104. Waldmann TA, Strober W and Mogielnicki RP. The renal handling of low molecular weight proteins II. Disorders of serum protein catabolism in patients with tubular proteinuria, the nephrotic syndrome, or uremia. J Clin Invest. 1972; 51:2162-2174.
105. Bergamaschi C, Bear J, Rosati M, Beach RK, Alicea C, Sowder R, Chertova E, Rosenberg SA, Felber BK and Pavlakis GN. Circulating IL-15 exists as heterodimeric complex with soluble IL- 15Ra in human and mouse serum. Blood. 2012; 120:e1-8.
106. Quinn LS. Interleukin-15: a muscle-derived cytokine regulating fat-to-lean body composition. J Anim Sci. 2008; 86:E75-83.
107. Riechman SE, Balasekaran G, Roth SM and Ferrell RE. Association of interleukin-15 protein and interleukin-15 receptor genetic variation with resistance exercise training responses. J Appl Physiol. 2004; 97:2214-2219.
108. Tamura Y, Watanabe K, Kantani T, Hayashi J, Ishida N and Kaneki M. Upregulation of circulating IL-15 by treadmill running in healthy individuals: Is IL-15 an endocrine mediator of the beneficial effects of endurance exercise? Endocr J. 2011; 58:211-215.
109. Quinn LS, Anderson BG, Strait-Bodey L and Wolden-Hanson T. Serum and muscle interleukin-15 levels decrease in aging mice: Correlation with declines in soluble interleukin-15 receptor alpha expression. Exp Gerontol. 2010; 45:106-112.
110. Marzetti E, Carter CS, Wohlgemuth SE, Lees HA, Giovannini S, Anderson B, Quinn LS and Leeuwenburgh C. Changes in IL-15 expression and death-receptor apoptotic signaling in rat gastrocnemius muscle with aging and life-long calorie restriction. Mech Ageing Dev. 2009; 130:272-280.
111. Harcourt LJ, Holmes AG, Gregorevic P, Schertzer JD, Stupka N, Plant DR and Lynch GS. Interleukin-15 administration improves diaphragm muscle pathology and function in dystrophic mdx mice. Am J Pathol. 2005; 166:1131-1141.
112. Carbó N, López-Soriano J, Costelli P, Busquets S, Alvarez B, Baccino FM, Quinn LS, López-Soriano FJ and Argilés JM. Interleukin-15 antagonizes muscle protein waste in tumourbearing rats. Br J Cancer. 2000; 83:526-531.
113. Quinn LS, Anderson BG, Drivdahl RH, Alvarez B and Argiles JM. Overexpression of interleukin-15 induces skeletal muscle hypertrophy in vitro: implications for treatment of muscle wasting disorders. Exp Cell Res. 2002; 280:55-63.
114. Gangemi S, Basile G, Monti D, Merendino RA, Di Pasquale G, Bisignano U, Nicita-Mauro V and Franceschi C. Age-related modifications in circulating IL-15 levels in humans. Med Inflam. 2005; 2005:245-247.
115. Nielsen AR, Hojman P, Erikstrup C, Fischer CP, Plomgaard P, Mounier R, Mortensen OH, Broholm C, Taudorf S, Krogh-Madsen R, Lindegaard B, Petersen AMW, Gehl J, et al. Association between interleukin-15 and obesity: interleukin-15 as a potential regulator of fat mass. J Clin Endocrinol Metab. 2008; 93:4486-4493.
116. Barra NG, Chew MV, Holloway AC and Ashkar AA. Interleukin-15 treatment improves glucose homeostasis and insulin sensitivity in obese mice. Diabetes Obes Metab. 2011; 14:190-193.
117. Quinn LS, Anderson BG, Strait-Bodey L, Stroud AM and Argiles JM. Oversecretion of interleukin-15 from skeletal muscle reduces adiposity. Am J Physiol Endocrinol Metab. 2009; 296:E191-202.
118. Lodolce JP, Boone DL, Chai S, Swain RE, Dassopoulos T, Trettin S and Ma A. IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity. 1998; 9:669-676.
119. Kennedy MK, Glaccum M, Brown SN, Butz EA, Viney JL, Embers M, Matsuki N, Charrier K, Sedger L, Willis CR, Brasel K, Morrissey PJ, Stocking K, et al. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med. 2000; 191:771-780.
120. Prlic M, Blazar BR, Farrar MA and Jameson SC. In vivo survival and homeostatic proliferation of natural killer cells. J Exp Med. 2003; 197:967-976.
121. Koka R, Burkett PR, Chien M, Chai S, Chan F, Lodolce JP, Boone DL and Ma A. Interleukin (IL)-15Ra-deficient natural killer cells survive in normal but not IL-15Ra-deficient mice. J Exp Med. 2003; 197:977-984.
122. Carson WE, Fehniger TA, Haldar S, Eckhert K, Lindemann MJ, Lai C-F, Croce CM, Baumann H and Caligiuri MA. A potential role for interleukin-15 in the regulation of human natural killer cell survival. J Clin Invest. 1997; 99:937-943.
123. Ranson T, Vosshenrich CAJ, Corcuff E, Richard O, Muller W and Di Santo JP. IL-15 is an essential mediator of peripheral NKcell homeostasis. Blood. 2003; 101:4887-4893.
124. Lugli E, Goldman CK, Perera LP, Smedley J, Pung R, Yovandich JL, Creekmore SP, Waldmann TA and Roederer M. Transient and persistent effects of IL-15 on lymphocyte homeostasis in nonhuman primates. Blood. 2010; 116:3238-3248.
125. Hesslein DG and Lanier LL. Transcriptional control of natural killer cell development and function. Adv Immunol. 2011; 109:45-85.
126. Schluns KS, Nowak EC, Cabrera-Hernandez A, Puddington L, Lefrancois L and Aguila HL. Distinct cell types control lymphoid subset development by means of IL-15 and IL-15 receptor a expression. Proc Natl Acad Sci USA. 2004; 101:5616-5621.
127. Dubois S, Mariner J, Waldmann TA and Tagaya Y. IL-15Ra recycles and presents IL-15 in trans to neighboring cells. Immunity. 2002; 17:537-547.
128. Stonier SW and Schluns KS. Trans-presentation: a novel mechanism regulating IL-15 delivery and responses. Immunol Lett. 2010; 127:85-92.
129. Mortier E, Advincula R, Kim L, Chmura S, Barrera J, Reizis B, Malynn BA and Ma A. Macrophage- and dendritic-cell-derived interleukin-15 receptor alpha supports homeostasis of distinct CD8+ T cell subsets. Immunity. 2009; 31:811-822.
130. Ota N, Takase M, Uchiyama H, Olsen SK and Kanagawa O. No requirement of trans presentations of IL-15 for human CD8 T cell proliferation. J Immunol. 2010; 185:6041-6048.
131. Wei X-q, Orchardson M, Gracie JA, Leung BP, Gao B-m, Guan H, Niedbala W, Paterson GK, McInnes IB and Liew FY. The sushi domain of soluble IL-15 receptor a is essential for binding IL-15 and inhibiting inflammatory and allogenic responses in vitro and in vivo. J Immunol. 2001; 167:277-282.
132. Mortier E, Quéméner A, Vusio P, Lorenzen I, Boublik Y, Grötzinger J, Plet A and Jacques Y. Soluble interleukin-15 receptor a (IL-15Ra)-sushi as a selective and potent agonist of IL- 15 action through IL-15Rb/g. J Biol Chem. 2006; 281:1612-1619.
133. Pillet AH, Bugault F, Theze J, Chakrabarti LA and Rose T. A programmed switch from IL-15- to IL-2-dependent activation in human NK cells. J Immunol. 2009; 182:6267-6277.
134. Huntington ND, Legrand N, Alves NL, Jaron B, Weijer K, Plet A, Corcuff E, Mortier E, Jacques Y, Spits H and Di Santo JP. IL-15 trans-presentation promotes human NK cell development and differentiation in vivo. J Exp Med. 2009; 206:25-34.
135. Bruunsgaard H, Pedersen AN, Schroll M, Skinhøj P and Pedersen BK. Decreased natural killer cell activity is associated with atherosclerosis in elderly humans. Exp Gerontol. 2001; 37:127-136.
136. Bouts AH, Out TA, Schroder CH, Monnens LA, Nauta J, Krediet RT and Davin JC. Characteristics of peripheral and peritoneal white blood cells in children with chronic renal failure, dialyzed or not. Perit Dial Int. 2000; 20:748-756.
137. Fairclough L, Urbanowicz RA, Corne J and Lamb JR. Killer cells in chronic obstructive pulmonary disease. Clin Sci (Lond). 2008; 114:533-541.
138. Morley JE, Thomas DR and Wilson MM. Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr. 2006; 83:735-743.
139. Newman AB, Kupelian V, Visser M, Simonsick EM, Goodpaster BH, Kritchevsky SB, Tylavsky FA, Rubin SM and Harris TB. Strength, but not muscle mass, is associated with mortality in the health, aging and body composition study cohort. J Gerontol A Biol Sci Med Sci. 2006; 61:72-77.
140. Ruiz JR, Sui X, Lobelo F, Morrow JR, Jr., Jackson AW, Sjostrom M and Blair SN. Association between muscular strength and mortality in men: prospective cohort study. BMJ. 2008; 337:a439.
141. Flegal KM, Graubard BI, Williamson DF and Gail MH. Excess deaths associated with underweight, overweight, and obesity. JAMA. 2005; 293:1861-1867.